Zhuangzhuang Li1,
Lingling Xie1 
,
Jinguang Wu1,
He Wang2,
Shugen Wang1,
Shugen Wang1,
For correspondence:- Lingling Xie Email: xielingling007@126.com Tel:+8615333275533
Accepted: 28 June 2021 Published: 30 July 2021
Citation: Li Z, Xie L, Wu J, Wang H, Wang S, Wang S, Effect of a combination of interferon-? and ambroxol on children with pneumonia, and on serum amyloid A: A randomized controlled study. Trop J Pharm Res 2021; 20(7):1505-1510 doi: 10.4314/tjpr.v20i7.25
© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the effect of combination of interferon-a with ambroxol on children with pneumonia, and its effect on serum amyloid A (SAA).
Methods: A total of 140 children who presented with pneumonia in Cangzhou Central Hospital from January 2019 to November 2020 were selected and randomly assigned to control group and study group. All the children were treated with conventional therapy against cough and phlegm, anti-infection, oxygen inhalation, antipyretic, water and electrolyte correction, and nutritional support. The control group received aerosol inhalation of ambroxol + physiological saline, in addition to conventional treatment. The study group was given aerosol inhalation of recombinant human interferon-α1b + ambroxol + physiological saline. The two groups were treated continuously for 7 days. The time taken for clinical symptoms to subside in each group, as well as serum levels of amyloid A (SAA), interleukin 6 (IL-6), immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG) before treatment and 7 days post-treatment were evaluated. Clinical efficacy and incidence of adverse reactions after 7 days of treatment were also obtained and compared.
Results: The time taken for symptom disappearance was significantly shorter in the study group than in control group, and inflammation indices were lower in the study group than in control group (p < 0.05). Levels of IgA, IgM, and IgG in the two groups after treatment were significantly elevated, but they were markedly higher in the observation group than in control group (p < 0.05). Clinical treatment efficacy was superior in the study group, relative to control (p < 0.05). However, no statistical disparity in incidence of adverse reactions was witnessed between the two groups (p > 0.05).
Conclusion: A combination of interferon-α1b and Ambroxol may be a boon in the treatment of children with pneumonia due to its efficacy and effect on inflammatory response and SAA levels.
Archives
News Updates
Fulltext in PDF